3rd – 5th May 2023
EPO will participate at the Cancer Immunotherapy Meeting (CIMT) Meeting 2023 in Mainz, Germany
The annual CIMT event is Europe’s largest immunotherapy meeting and EPO will be presenting its very recent developments in immune oncology research at this meeting in May 2023 in Mainz, Germany. We will be happy to meet everyone at our posters, who is interested in our research and services in immune oncology, humanized mouse and PDX models for scientific exchange and discussions.
- Poster # 115: Human leukocyte antigen (HLA) matching of cancer patient-derived xenografts (PDX) models with immune cell-humanized mice
- Matching of human leukocyte antigen (HLA) profiles of patient-derived xenografts (PDX) with human immune cell populations that are used for humanization of mouse models is a prerequisite for testing immune checkpoint inhibitors and mimics closer the clinical situation.
- HLA profiles of 291 established PDX models from 18 different tumor entities were analyzed and matched to known peripheral blood mononuclear cell (PBMC) donors according to the donor-recipient HLA matching criteria recommended by the Blood and Marrow Transplant Clinical Trials Network.
- HLA-matched PDX and immune cells were engaged in an in vivo model and showed a response to checkpoint inhibition.
- Poster # 273: Humanized mouse models for the preclinical evaluation of novel cancer immunotherapy options
- The preclinical evaluation of many novel immune therapies requires the use mouse models with a functional human immune system. To this end, we have established human tumor-immune-cell models of different entities using CDX or PDX in combination with different donor derived immune cell subsets as effector cells.
- Our human tumor-immune-cell models allow preclinical, translational studies on tumor immune biology as well as evaluation of new therapies, drug combinations and biomarker identification and validation.
Download this poster (5th May 2023)